|
$128,597
|
To conduct observational research and planning that will inform the research design for the My Brother?s Keeper School Success Mentor and Student Support Initiative.
|
2016 - 2017
|
LJAF
|
|
$250,642
|
To support the development of a tool that rates the transparency of evidence-based programs and social intervention evaluations.
|
2017 - 2018
|
LJAF
|
|
$218,170
|
To study the impact of the Affordable Care Act on public safety.
|
2014 - 2015
|
LJAF
|
|
$397,721
|
To conduct a randomized controlled trial on impacts of school-based vision care services in Chicago Public Schools.
|
2017 - 2021
|
LJAF
|
|
$299,166
|
To provide general operating support for the Center for Research and Reform in Education.
|
2017 - 2020
|
LJAF
|
|
$302,625
|
To provide general operating support for the Center for Research and Reform in Education.
|
2016 - 2018
|
LJAF
|
|
$3,575,140
|
To develop research on policy options that maximize access to and affordability of prescription drugs.
|
2016 - 2019
|
LJAF
|
|
$434,890
|
To support the evaluation of medication assisted treatment (MAT) provider networks in Medicaid managed care plans, to advance access to MAT.
|
2020 - 2022
|
LJAF
|
|
$668,593
|
To research and support the establishment of model substance use disorder treatment program licensure and accreditation policies.
|
2020 - 2023
|
LJAF
|
|
$154,524
|
To support efforts to increase the number of organ transplants and reduce the number of individuals on the waiting list.
|
2016 - 2018
|
LJAF
|
|
$157,560
|
To support efforts to improve transparency at the Food and Drug Administration.
|
2016 - 2018
|
LJAF
|
|
$251,225
|
To conduct research and develop recommendations to improve the United States Department of Health and Human Services Organ Procurement and Transplantation Network system.
|
2018 - 2019
|
LJAF
|
|
$293,317
|
To evaluate the consequences of state policies limiting opioid prescriptions.
|
2019 - 2021
|
LJAF
|
|
$293,884
|
To evaluate emerging health system and payer interventions to reduce overuse of postsurgical opioid prescribing for acute pain.
|
2019 - 2021
|
LJAF
|
|
$315,697
|
To evaluate a family planning program administered in the Baltimore City Booking and Intake Center.
|
2018 - 2021
|
LJAF
|
|
$318,000
|
To increase the availability and affordability of life-saving drugs while maintaining incentives for innovation in drug development.
|
2015 - 2017
|
LJAF
|
|
$344,944
|
To support the Center for Research and Reform in Education at Johns Hopkins University.
|
2020 - 2022
|
LJAF
|
|
$371,754
|
To (i) assess beliefs and attitudes about medication treatment for opioid use disorder (?MOUD?) among decision makers within the criminal justice system and (ii) evaluate the Delaware Department of Corrections' MOUD program, with the overall goal of incre
|
2019 - 2021
|
LJAF
|
|
$449,889
|
To fund a study to estimate the impacts of school-based vision services in Baltimore City Public Schools.
|
2016 - 2020
|
LJAF
|
|
$500,000
|
To develop and disseminate a standardized data structure for National Institute on Drug Abuse Treatment Clinical Trials Network data.
|
2018 - 2021
|
LJAF
|
|
$696,583
|
To analyze the frequency of predatory medical billing practices by hospitals that sue and garner the wages of low wage patients and increase awareness of these practices to inform policy changes that protect patients.
|
2019 - 2021
|
LJAF
|
|
$841,756
|
To provide nonpartisan policy recommendations and technical support to interested states related to reducing health care prices.
|
2018 - 2021
|
LJAF
|
|
$940,607
|
To promote the adoption of a waste-free prescription drug formulary by private corporations in place of the current drug rebate system.
|
2018 - 2021
|
LJAF
|
|
$1,372,005
|
To fund a randomized controlled trial of the My Brother?s Keeper Success Mentors and Student Support Initiative.
|
2016 - 2023
|
LJAF
|
|
$3,693,484
|
To fund a randomized controlled trial of the Talent Development Secondary Diplomas Now program.
|
2015 - 2018
|
LJAF
|
|
$4,251,144
|
To develop and disseminate research on policy options that maximize access to and affordability of prescription drugs without stifling innovation.
|
2019 - 2022
|
LJAF
|
